EcoDrugPlus

Renin

Ensembl ID : ENSFHEG00000004239
Gene Symbol: REN
3 Cross references
220 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSFHEG00000014536
Gene Symbol: RET
3 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Rxr-Beta-A

Ensembl ID : ENSFHEG00000014238
Gene Symbol: LOC105926355
3 Cross references
211 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSFHEG00000018939
Gene Symbol: RARB
4 Cross references
393 Possible Orthologues:

Retinoic Acid Receptor Beta-Like

Ensembl ID : ENSFHEG00000009990
Gene Symbol: LOC105935556
2 Cross references
380 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSFHEG00000023364
Gene Symbol: RARG
4 Cross references
383 Possible Orthologues:

Retinoic Acid Receptor Gamma-A-Like

Ensembl ID : ENSFHEG00000008664
Gene Symbol: LOC105939073
3 Cross references
367 Possible Orthologues:

Retinoid X Receptor Alpha

Ensembl ID : ENSFHEG00000014693
Gene Symbol: RXRA
3 Cross references
231 Possible Orthologues:

Rho-Associated Protein Kinase 1-Like

Ensembl ID : ENSFHEG00000003438
Gene Symbol: LOC105924233
4 Cross references
210 Possible Orthologues:

Rho-Associated Protein Kinase 1-Like

Ensembl ID : ENSFHEG00000021123
Gene Symbol: LOC105930740
3 Cross references
214 Possible Orthologues:

Ribosomal Protein L10

Ensembl ID : ENSFHEG00000011386
Gene Symbol: RPL10
3 Cross references
407 Possible Orthologues:

Ribosomal Protein L10a

Ensembl ID : ENSFHEG00000004562
Gene Symbol: RPL10A
3 Cross references
380 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).